PATENT CLAIM ANALYSIS

Application Number: 15955960
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-08
Patent Classification: ["424", "133100"]

Abstract:
We achieved the present invention on the basis of the finding that an excellent therapeutic effect against pancreatic cancer can be obtained by administering an IL-6 inhibitor and an antimetabolite to pancreatic cancer patients. We also found that metastatic lesions from human pancreatic cancer can be reduced and ascites can be eliminated.

Claim (Index 2):
The method of  claim 1 , wherein the anti-IL-6 receptor antibody is a chimeric antibody, a humanized antibody or a human antibody.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 91.0
- Lexical Diversity: 1.42105
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['13700355', '12161733', '12085065', '12733951', '14812681']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6707343751065705
- 35 USC 102 Novelty (BERT): 0.4612731164500219
- Combined Prediction Score: 0.6497882492409156
- Mean Citation Score: 178.961924
- Max Citation Score: 216.78017000000003
- Similarity Product: 215.0235457715524

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test